Archived on 26 November 2021 at 6:00 am [URL redacted]
@MathewBussy [name pseudonymized] [03]: @ZubyMusic #woke #noble #freedom #justice #civil [URL redacted]

https://www.bitchute.com/video/s1nPYDj7KBEQ/ #2017_EuropaTheLastBattle i.e. https://www.imdb.com/title/tt7528992/ #ConspiracyTheoryNewWorldOrderNWO #BeliefJudaism #IdentityJewishZionism #PoliticsCommunism #PhenomnFrankfurtSchool #AdvocacyUKFabianSociety i.e. https://fabians.org.uk/about-us/ #PoliticallyCorrectPC #ConspiracyTheoryCulturalMarxism #IndivHistoricalFigureKarlMarx #SlurPaedophilia #1932_Holodomor


Context: response to tweet (including a screen-shot) of page 24 of the #OrgUSFedFoodAndDrugAdministrationFDA https://www.fda.gov/media/151733/ 'Summary Basis for Regulatory Action' (8 November 2021) - downloadble from: https://www.fda.gov/media/151733/download i.e.
"Moreover, since vaccine-associated myocarditis/pericarditis is the most clinically significant identified risk, FDA undertook a quantitative benefit-risk assessment to model the excess risk of myocarditis/pericarditis vs. the expected benefits of preventing COVID- 19 and associated hospitalizations, ICU admissions, and deaths. For estimation of risk, the model took a conservative approach by relying on non-chart-confirmed cases from a US healthcare claims database (OPTUM) that could provide a control group and greater confidence in denominators for vaccine exposures. Thus, the estimates of excess risk in this model are higher than the rates estimated from reports to VAERS (an uncontrolled passive surveillance system), with an estimated excess risk approaching 200 cases per million vaccinated males 16-17 years of age (the age/sex-stratified group with the highest risk). For estimation of benefit, the model output was highly dependent on the assumed COVID-19 incidence, as well as assumptions about vaccine efficacy and duration of protection. The assessment therefore considered a range of scenarios including but not limited to a 'most likely' scenario associated with recent Delta variant surge and diminished vaccine effectiveness (70% overall, 80% against COVID-19 hospitalization) compared to that observed in the clinical trial. The 'worst-case' scenario with low COVID-19 incidence reflecting the July 2021 nadir and the same somewhat diminished vaccine effectiveness as in the 'most likely' scenario.
For males and females 18 years of age and older and for females 16-17 years of age, even before accounting for morbidity prevented from non-hospitalized COVID-19, the model predicts that the benefits of prevented COVID-19 hospitalizations, ICU admissions and deaths would clearly outweigh the predicted excess risk of vaccine-associated myocarditis/pericarditis under all conditions examined. For males 16-17 years of age, the model predicts that the benefits of prevented COVID-19 hospitalizations, ICU admissions and deaths would clearly outweigh the predicted excess risk of vaccine-associated myocarditis/pericarditis under the 'most likely' scenario, but that predicted excess cases of vaccine-associated myocarditis/pericarditis would exceed COVID-19 hospitalizations and deaths under the 'worst case' scenario. However, this predicted numerical imbalance does not account for the greater severity and length of hospitalization, on average, for COVID-19 compared with vaccine-associated myocarditis/pericarditis. Additionally, the 'worst case' scenario model predicts prevention of >13,000 cases of non-hospitalized COVID-19 per million vaccinated males 16-17 years of age, which would include prevention of clinically significant morbidity and/or long-term sequelae associated with some of these cases. Finally, the model does not account for indirect societal/public health benefits of vaccination. Considering these additional factors, FDA concluded that even under the 'worst case' scenario the benefits of vaccination sufficiently outweigh risks to support approval of the vaccine in males 16-17 years of age." #OtheringOutGroupAntiVaxxer
Supplementary: "CDC continues to recommend that everyone ages 5 years and older get vaccinated for COVID-19. The known risks of COVID-19 illness and its related, possibly severe complications, such as long-term health problems, hospitalization, and even death, far outweigh the potential risks of having a rare adverse reaction to vaccination, including the possible risk of myocarditis or pericarditis." https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html #_Focal

#PoliticsFascismNaziSympathizerSavitriDevi #PowerControlSegregationEthnopluralism i.e. https://en.wikipedia.org/wiki/Ethnopluralism #PoliticsNationalismWhite


Supplementary: #MetaphorVersusCompetitionCooperation

https://www.youtube.com/watch?v=IvIfk7TSB1Q http://www.tacticalmediafiles.net/videos/45022/Meme-Wars_-Internet-culture-and-the-_alt_right_-
----------------------------------------------------
Similar use of the #MetaphorGardenGardener, this time by #IndivComedianRosieHolt's #PhenomnSatire of #OrgClassifPPUKConservativesLizTruss and #OrgClassifPPUKConservativesKwasiKwarteng's #2022_UKGovernmentMiniBudget: "We're not trickling down. We are watering a whole garden. Selectively. If you're watering a garden, do you water everything in it? Some would argue yes, but I would say no. You water the lovely flowers and not the weeds." https://twitter.com/RosieisaHolt/status/1573353483566288896 #PhenomnSatire #MetaphorTrickleDownEconomics https://www.reuters.com/article/factcheck-rosieholt-conservative-idUSL1N3150X8


Addendum: very reminiscent of arguments for #PowerControlSegregationApartheid such as: "In January 1944, D. F. Malan, speaking as Leader of the Opposition, became the first person to employ it in the South African parliament. A few months later he elaborated, 'I do not use the term 'segregation', because it has been interpreted as a fencing off (afhok), but rather 'apartheid', which will give the various races the opportunity of uplifting themselves on the basis of what is their own.'" (Giliomee, 2003, p. 374).
Giliomee, H., 2003. 'The Making of the Apartheid Plan, 1929-1948*'. Journal of Southern African Studies, 29(2), pp.373-392 i.e. https://doi.org/10.1080/03057070306211 #IndivHistoricalFigureDanielMalan #NoRAfricaSouthAfrica

[1110]